Document:

exh10-1_080714

Exhibit 10.1

AGREEMENT

This Agreement (this “Agreement”) is entered into effective as of August 7, 2014 (the “Effective Date”), by and between Cloud Peak Energy Logistics LLC, an Oregon limited liability company (“CPEL”), and Coal Valley Resources, Inc., an Alberta corporation (“CVRI”).  CPEL and CVRI are referred to individually as a “Party” and collectively as Parties”.

BACKGROUND

A.     CVRI and CPEL are individually parties to certain contracts with Westshore Terminals Limited Partnership (“Westshore”) for coal unloading, storage and vessel loading services at Westshore’s export terminal at Roberts Bank, British Columbia (“Westshore Terminal”).

B.    CPEL desires to increase its contracted throughput capacity at Westshore Terminal.  

C.    Westshore Terminal currently lacks excess capacity.

D.     Westshore has indicated to CPEL that additional capacity could be provided to CPEL if CVRI terminated its contract(s) with Westshore, and Westshore has indicated its consent to such CVRI termination and increased capacity to CPEL.

E.    CVRI agrees to terminate such contract(s) with Westshore in exchange for a payment from CPEL, as contemplated by this Agreement.

AGREEMENT

NOW, THEREFORE, in consideration of the various transactions set forth herein, the Parties hereby agree as follows:

1.Payment.  In consideration of the actions of CVRI as contemplated hereunder, CPEL agrees to pay CVRI an amount equal to Thirty Seven Million Dollars ($37,000,000.00) in United States currency (the “Payment”).  The Payment will be made in a single lump sum by a wire transfer of immediately available funds, to a bank account designated by CVRI, no later than 3 U.S. business days after the Effective Date.     

2.Representations.  CVRI hereby represents and warrants to CPEL as of the date hereof and as of the date of the Payment that (i) CVRI is the sole party to any and all agreements (written, oral or otherwise) relating to CVRI’s or any of its affiliates’ capacity or other dealings with the Westshore Terminal, (ii) no affiliate of CVRI is a party to any such agreements, (iii) CVRI has executed an agreement (“CVRI Termination Agreement”) with Westshore containing an irrevocable, binding, and complete termination of all agreements for terminal services at the Westshore Terminal and any other business dealings among CVRI and its affiliates involving the Westshore Terminal effective no later than January 1, 2015 and (iv) CVRI and all of its applicable affiliates have obtained all board and other internal or third party approvals and consents to enter into and consummate the transactions contemplated by this Agreement.  

3.Public Disclosures.  

(a)Any press release or public statement issued at any time hereafter by a Party or its affiliates concerning this Agreement or the transactions contemplated by this Agreement will be subject to the prior approval of the other Party, which consent shall not be unreasonably withheld or delayed.  

(b)Nothing in this Section 3 shall prohibit a Party’s ability to make such disclosures as are required, in the sole judgment of such Party, by applicable law, including federal securities laws, rules or regulations or the requirements of any exchange on which a Party’s (or its affiliate’s) securities may be listed, quoted or traded, provided that the Party required, in its sole judgment, to make such disclosure shall allow the other Party reasonable time to review and comment on any such press release or other disclosure prior to the issuance thereof.  

4.Notices.  All notices hereunder will be given in writing and will be deemed to have been given (i) on the date of delivery, when delivered personally or by overnight courier or sent by facsimile or when confirmed in a reply email if sent electronically, or (ii) three U.S business days after being deposited in the U.S. or Canadian mail, as certified, postage prepaid, and sent to the address below (or to such other address designated by such Party in accordance with this provision):  

	
		
	If to CPEL:
Cloud Peak Energy Logistics LLC
385 Interlocken Crescent, Suite 400
Broomfield, CO  80021 
Attn: Sr. V.P - Business Development
Facsimile: 720-566-3092 
	If to CVRI:
Coal Valley Resources, Inc.
1100, 10123 - 99th Street 
Edmonton, Alberta T5J 3H1 
Attn:  General Counsel
Facsimile:  780-420-5878

5.Assignment.  Neither Party will assign this Agreement, in whole or in part, without the prior written consent of the other Party, except that only a written notice and not a prior written consent will be required for assignment to wholly-owned affiliated entities. This Agreement will be binding upon and inure to the benefit of the Parties hereto and their successors and permitted assigns.  

6.Amendments and Waiver.  No amendment to this Agreement will be effective unless it is in writing and signed by both Parties.  No waiver by either Party of any term of this Agreement, in any one or more instances, will be deemed to be or construed as a waiver of any other term of this Agreement.  A waiver of any term of this Agreement must be in writing and signed by the waiving Party.

7.Costs and Expenses.  Each Party shall be responsible for its own costs and expenses incurred in connection with the transactions contemplated by this Agreement.

8.Counterparts. This Agreement may be executed by facsimile or by e-mail of a signed Agreement to the other Party and in counterparts, all of which will be considered one and 

2

the same agreement, and will become effective when counterparts have been signed by each of the Parties and delivered to each other Party.

9.Entire Agreement.  This Agreement constitutes the entire agreement and understanding between the Parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to such subject matter.

10.Further Assurances.  If any further action is reasonably necessary to carry out the purpose of this Agreement, then each Party will take such further action (including the execution and delivery of further documents) as the other Party reasonably requests to carry out such purpose.  

11.Governing Law.  This Agreement will be governed by and construed in accordance with the laws of the State of Colorado, without regard to conflicts-of-law principles.  

12.No Third Party Beneficiaries.  This Agreement is for the sole benefit of the Parties hereto and their affiliates, successors and permitted assigns, and nothing herein expressed or implied will give or be construed to give to any person or entity, other than the Parties hereto and such affiliates, successors and permitted assigns, any legal or equitable rights hereunder.   

13.Specific Performance.  Each of the Parties acknowledges that the other Party would not have an adequate remedy at law for money damages in the event that any of the covenants or agreements of the other Parties set forth in this Agreement were not performed in accordance with its terms and therefore agrees that the affected Party shall be entitled to specific performance or injunctive and other equitable relief in addition to any other remedy to which it may be entitled, at law or in equity.

*    *    *    *    *

3

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed effective as of the Effective Date.

	
	
	CLOUD PEAK ENERGY LOGISTICS LLC 

	 

	 

	By: /s/ Colin S. Marshall

	Name: Colin S. Marshall

	Title: President and Chief Executive Officer

	 

	 

	 

	 

	COAL VALLEY RESOURCES, INC.

	 

	 

	By: /s/ Lynette Stanley-Maddocks

	Name: Lynette Stanley-Maddocks

	Title: General Counsel

4EX-10.6

 Exhibit 10.6 

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS
BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 MANUFACTURING AND SUPPLY AGREEMENT 

THIS MANUFACTURING AND SUPPLY AGREEMENT (the “AGREEMENT”) is made effective as of the 27th day of September, 2004 (the
“EFFECTIVE DATE”), by and between SANTARUS, INC., a Delaware corporation, having offices at 10590 West Ocean Air Drive, Suite 200, San Diego, California 92130, U.S.A. (“SANTARUS”) and OSG Norwich Pharmaceuticals Inc., a Delaware
corporation, having offices at 6826 State Highway 12, Norwich, New York 13815 (“MANUFACTURER”). Manufacturer and Santarus are sometimes referred to herein individually as a “PARTY” and collectively as the “PARTIES.”

 RECITALS 
 WHEREAS,
Santarus is a specialty pharmaceutical company focused on acquiring, developing and commercializing products for the prevention and treatment of gastrointestinal diseases and disorders; 

WHEREAS, Manufacturer is a provider of outsourced drug development and manufacturing services to pharmaceutical and biotechnology companies;

 WHEREAS, Santarus seeks to retain a contract manufacturer to manufacture and supply commercial quantities of its SAN-10 immediate-release
omeprazole pharmaceutical product; 
 WHEREAS, Manufacturer possesses substantial resources, experience, and expertise in the manufacture of
pharmaceutical products; and 
 WHEREAS, the Parties mutually desire to enter into an agreement for the commercial manufacture and supply of
Santarus’ SAN-10 product. 
 NOW THEREFORE, in consideration of the foregoing and the mutual covenants and agreements set forth below
and in the Quality Agreement, the Parties agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 1.1
“AFFILIATE” means any individual, corporation, association, or other business entity, which directly or indirectly controls, is controlled by, or is under common control with the Party in question. As used in this definition of
“Affiliate,” the term “control” shall mean, as to 

  
 1 

 
an entity, (a) direct or indirect ownership of [***] percent [***] or more of the voting interests or other ownership interests in the entity in question; (b) direct or indirect
ownership of [***] percent [***] or more of the interest in the income of the entity in question; or (c) possession, directly or indirectly, of the power to direct or cause the direction of management or policies of the entity in question
(whether through ownership of securities or other ownership interests, by contract or otherwise). 
 1.2 “API” means the active
pharmaceutical ingredient known as omeprazole (Chemical Abstract No. 73590-58-6). 
 1.3 “API REIMBURSEMENT VALUE” means
[***]. 
 1.4 “APPLICABLE LAWS” mean all laws, statutes, ordinances, codes, rules, regulations, guidelines, and procedures enacted
or made by a Government Authority, including, without limitation, the FDA and any applicable Foreign Regulatory Authority, that are in force during the Term, and in each case only to the extent applicable to the subject matter of, or the performance
by the Parties of their respective obligations under, this Agreement. For purposes of this Agreement, “Applicable Laws” shall include, without limitation, the FFDCA, the regulations promulgated thereunder (including, without limitation,
those regulations currently contained in Title 21 of the Code of Federal Regulations), and other rules and regulations promulgated under the FFDCA relating to the manufacture of pharmaceutical products; and equivalent laws, regulations and standards
promulgated by a Government Authority that may assert jurisdiction over the Finished Product or any applicable Manufacturer manufacturing facilities; GMP, including the FDA’s Guidance for Industry, Manufacturing, Processing or Holding Active
Pharmaceutical Ingredients, March 1998, and any updates thereto; and the FDA’s regulations for drug establishment registration. 
 1.5
“BULK API” means the bulk form of API manufactured by a Third Party manufacturer and provided to Manufacturer for use in manufacturing the Finished Product in accordance with the terms and conditions of this Agreement. 

1.6 “BUSINESS DAY” means any day other than a Saturday, Sunday or statutory holiday in San Diego, California. 

1.7 “CERTIFICATES OF COMPLIANCE” means (a) the certificate of analysis confirming the identity, strength, quality and purity of
each invoiced batch of Finished Product to which it pertains (together with any certificate of analysis pertaining to the Bulk API contained in such batch), (b) the certificate of compliance confirming that the each invoiced batch of Finished
Product was manufactured, tested, stored and supplied by Manufacturer in compliance with this Agreement, including without limitation the Specifications, GMP and Applicable Laws, and (c) such other certificates and confirmations as described in
the Quality Agreement, each such certificate signed by an authorized signatory of Manufacturer. 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 2 

 1.8 “COMMENCEMENT OF COMMERCIAL MANUFACTURING” means the date on which Manufacturer
commences to manufacture commercial quantities of Finished Product pursuant to the first Firm Purchase Order submitted by Santarus under Section 2.2.3. 

1.9 “DEFICIENCY NOTICE” has the meaning set forth in Section 3.5.1. 

1.10 “EFFECTIVE DATE” has the meaning specified on the first page of this Agreement. 

1.11 “FACILITY” means Manufacturer’s facilities located at 6826 State Highway 12, Norwich, New York 13815, and any other
facilities (including facilities utilized by subcontractors as permitted hereunder) that are used in connection with the activities performed by Manufacturer hereunder and are approved in writing by Santarus. 

1.12 “FDA” means the United States Food and Drug Administration, and any successor thereto. 

1.13 “FFDCA” means the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. Section 321 et seq., as amended. 

1.14 “FINISHED PRODUCT” means Santarus’ SAN-10 immediate-release omeprazole pharmaceutical product, as more particularly
described in the Specifications. 
 1.15 “PURCHASE ORDER” has the meaning set forth in Section 2.2.3. 

1.16 “FORECAST” has the meaning set forth in Section 2.2.2. 

1.17 “FOREIGN REGULATORY AUTHORITY” means, for each country other than the United States of America, the authority or authorities
having jurisdiction over the Finished Product that correspond to the FDA. 
 1.18 “GMP” means current good manufacturing practices
applicable in the United States of America as described in: 
 (a) Parts 210 and 211 of Title 21 of the United States Code of Federal
Regulations and the requirements imposed thereunder by the FDA, together with the latest FDA guidance and like documents pertaining to manufacturing and quality control practice, all as updated, amended and revised from time to time. 

1.19 “GOVERNMENT AUTHORITY” means any supra-national, national, regional, state, provincial or local government, court, governmental
agency, authority, board, bureau, instrumentality or regulatory body having jurisdiction over the Finished Product. 
 1.20 “INDA”
means an investigational new drug application. 
 1.21 “MANUFACTURER EQUIPMENT” has the meaning set forth in Section 14.1.

  
 3 

 1.22 “MANUFACTURER SUPPLY COMMITMENT” has the meaning set forth in Section 2.2.4.

 1.23 “INITIAL TERM” has the meaning set forth in Section 11.1. 

1.24 “INVENTION” means information relating to any invention, innovation, improvement, development, discovery, computer program,
device, trade secret, method, know-how, process, technique or the like, whether or not written or otherwise fixed in any form or medium, regardless of the media on which it is contained and whether or not patentable or copyrightable. 

1.25 “MINIMUM RUN QUANTITY” means the minimum number of batches of Finished Product to be produced during the same cycle of
manufacturing as set forth in EXHIBIT A hereto. 
 1.26 “NDA” means a New Drug Application filed with the FDA for marketing
approval for a pharmaceutical product. 
 1.27 “MANUFACTURER MANUFACTURING RESPONSIBILITIES” has the meaning specified in
Section 3.1 of this Agreement. 
 1.28 “PRICE” means the price for the manufacture and supply of Finished Product under this
Agreement specified in the pricing structure set forth in EXHIBIT B, as may be amended from time to time in accordance with Section 6.2 of this Agreement. 

1.29 “PRODUCT PATENTS” means (i) United States patents 6,489,346 and 5,840,737, (ii) [***] and (iii) [***]. 

1.30 “QUALITY AGREEMENT” means that certain quality agreement to be entered into by and between the Parties, following the Effective
Date but reasonably in advance of the Commencement of Commercial Manufacturing, and relating to the obligations of the Parties regarding procedures to assure the identity, strength, purity and quality of the Finished Product. 

1.31 “RAW MATERIALS” has the meaning set forth in Section 7.1. 

1.32 “REGULATORY APPROVAL” means, with respect to a national or multinational jurisdiction, any approvals, licenses, registrations,
or authorizations necessary for the manufacture (where relevant), marketing and sale of the Finished Product in such nation or jurisdiction. 

1.33 “RENEWAL TERM” has the meaning set forth in Section 11.1. 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 4 

 1.34 “RESPONSIBLE EXECUTIVE” means the President or the Chief Executive Officer of a
Party, or his or her designated representative. 
 1.35 “SECONDARY MANUFACTURER SUPPLY COMMITMENT” has the meaning set forth in
Section 2.2.4. 
 1.36 “SPECIFICATIONS” means the specifications for the Finished Product set forth in the Quality Agreement
(as amended from time to time) together with applicable manufacturing protocols, packaging specifications, testing methodologies and all applicable requirements set forth in regulatory filings made with the FDA (including INDA’s and NDA’s)
for the Finished Product. 
 1.37 “TERM” means the Initial Term and the Renewal Term. 

1.38 “TERRITORY” means the United States of America. 

1.39 “THIRD PARTY” means any individual or entity other than Manufacturer or Santarus or their respective Affiliates. 

ARTICLE 2 
 SUPPLY,
STORAGE, AND DELIVERY OF FINISHED PRODUCT 
 2.1 SUPPLY OF FINISHED PRODUCT. During the Term, subject to Section 2.2.4,
Manufacturer shall manufacture and supply, in accordance with the provisions of this Agreement, the Specifications, GMP and Applicable Laws, [***]. 

2.2 COMMERCIAL SUPPLY. 
 2.2.1
Supply Obligations. Manufacturer shall manufacture and supply to Santarus, and Santarus agrees to purchase from Manufacturer, such quantities of Finished Product specified by Santarus in accordance with this Agreement at the Price. [***]. 

2.2.2 Forecasts. 
 Santarus
shall use commercially reasonable efforts to determine its estimated requirements for Finished Product from Manufacturer and shall deliver to Manufacturer a written, non-binding, rolling [***] month forecast, by month, of such estimated requirements
(the “FORECAST”). Santarus shall deliver the first Forecast to Manufacturer (the “INITIAL FORECAST”) as soon as reasonably practicable following the execution of this Agreement. After delivery of the Initial Forecast, Santarus
shall, in accordance with the terms of this Agreement, update and revise the Forecast on a not less than [***] basis. 
 Santarus shall
provide each updated Forecast not less than [***] calendar days prior to the beginning of the next [***]. Manufacturer shall use the Forecast for planning purposes and make available the production capacity and associated testing and release
capacity required to manufacture and supply the forecasted quantities of Finished Product within the time frames specified in each Forecast. 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 5 

 2.2.3 Purchase Orders. Santarus shall submit to Manufacturer a written purchase order (the
“PURCHASE ORDER”) for the purchase of Finished Product at least [***] calendar days prior to the specified delivery date. Each Purchase Order shall specify the quantity or, if more than one shipment is requested, quantities of Finished
Product ordered, the requested delivery date or dates, the delivery address(es) and any applicable shipping information (if different from that specified in Section 2.3). Manufacturer shall manufacture and supply the Finished Product in the
quantities and by the delivery dates set forth in the applicable Purchase Order. 
 2.2.4 Supply Commitment. 

Manufacturer shall supply to Santarus [***] (the “MANUFACTURER SUPPLY COMMITMENT”) and Manufacturer further agrees to [***] (the
“SECONDARY MANUFACTURER SUPPLY COMMITMENT”). Manufacturer shall ensure that adequate Manufacturing Equipment (as defined in Section 14.1 below) is available and dedicated to fulfill the supply and that such Manufacturing Equipment is
maintained in good working order. 
 2.2.5 Purchase Order Amendments. Santarus may amend a Purchase Order by submitting an amended Purchase
Order, as follows: [***]. 
 2.3 SHIPPING AND DELIVERY OF FINISHED PRODUCT. Manufacturer shall serve as agent for Santarus, arrange for
shipping and insurance so that the Finished Product will be delivered to the delivery address on the delivery date set forth in the applicable Purchase Order, at Santarus’ expense. Santarus may select the freight carrier used by Manufacturer to
ship Finished Products and may monitor Manufacturer’s shipping and freight practices as they pertain to this Agreement. Finished Products shall be transported in accordance with the Specifications, GMP and Applicable Laws. Manufacturer shall
notify Santarus in writing at the time of shipment as to the quantity of Finished Product shipped, the identity of the carrier and the anticipated delivery date. If any order is delayed and is not likely to be delivered on time, Manufacturer shall
immediately notify Santarus and Santarus may direct Manufacturer to ship such order by expedited means of transportation as designated by Santarus. [***]. 

2.4 TITLE AND RISK OF LOSS. Manufacturer shall deliver the Finished Product to the carrier selected by Santarus at Manufacturer’s
shipping point unless otherwise mutually agreed in writing. Such title as Manufacturer has in Finished Products and risk of loss or of damage to Finished Products shall remain with Manufacturer until Finished Products are loaded onto the
carrier’s vehicle by Manufacturer for shipment at Manufacturer’s shipping point at which time title and risk of loss or damage shall transfer to Santarus. Except as expressly provided otherwise in this Agreement, Santarus shall be
responsible for all charges associated with shipping of Finished Product. 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 6 

 2.5 DOCUMENTATION AND CUSTOMS. Upon completion of manufacturing, packaging and testing of
Finished Product pursuant to each Purchase Order, Manufacturer shall deliver to Santarus by electronic means quality documentation for such Finished Product manufactured pursuant to such Purchase Order as specified in the Quality Agreement,
including without limitation, the Certificates of Compliance in respect of such Purchase Order and, if requested by Santarus, completed batch production records (collectively, the “PRE-SHIPPING DOCUMENTATION”). Manufacturer acknowledges
and agrees that Santarus shall be responsible, at all times, for the final release of the Finished Product and accordingly, Manufacturer shall not ship any Finished Product until Santarus has notified Manufacturer in writing that it has completed
its final release. 
 Concurrent with the shipment of each Purchase Order of Finished Product, Manufacturer shall deliver to Santarus any
applicable documentation corresponding to such shipment and such other documentation and information as may be necessary or desirable for complying with import, export, and customs laws, regulations and like requirements, as applicable. 

2.6 INVOICES. MANUFACTURER SHALL INVOICE SANTARUS ON [***] AND SANTARUS SHALL PAY [***] FOLLOWING RECEIPT THEREOF (IN ACCORDANCE WITH SECTIONS
6.3 AND 15.5 BELOW). 
 2.7 LATE DELIVERY/SHORTAGES AND OVERAGES. 

[***]. 
 2.8 KEY PERFORMANCE INDICATORS. 

2.8.1 For each [***] period during the Term, Manufacturer shall meet or exceed the key performance indicators established in good faith by
Manufacturer and Santarus for such [***] period (collectively, as established with respect to the applicable [***] period, the “KPIS”). The preliminary categories of KPIs in respect of the first [***] period following Commencement of
Commercial Manufacturing are set forth in EXHIBIT C, and the parties mutually agree to refine such KPIs reasonably in advance of the Commencement of Commercial Manufacturing. Thereafter, the KPIs will be reviewed by Manufacturer and Santarus at each
[***] review meeting contemplated by Section 2.12 with the intention of amending, if necessary, the KPIs in respect of the forthcoming [***] period. If no such amendments are necessary or if amendments are not agreed, the KPIs in respect of
such forthcoming [***] period shall be at least as beneficial to Santarus as the KPIs for the then current [***] period. 
 2.8.2 In the
event that Manufacturer fails to meet one or more of the KPIs at any time during the term of this Agreement, then Manufacturer and Santarus shall work diligently to address such failure including, without limitation, the following: 

(i) Manufacturer’s Customer Service Director and the Senior Manager of Supply Chain Management of Santarus shall meet
within five (5) days of the 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 7 

 
determination of the sustained failure in order to establish a procedure to address the problem (the “REMEDIATION PLAN”). If such meeting does not occur within such five (5) days
or if there is no agreement as to the Remediation Plan (a “STAGE 1 FAILURE”), then clause (ii) shall apply; 

(ii) Manufacturer’s Plant Manager and the Director of Manufacturing of Santarus shall meet within five (5) days of
the Stage 1 Failure in order to establish a Remediation Plan. If such meeting does not occur within such five (5) days or if there is no agreement as to the Remediation Plan (a “STAGE 2 FAILURE”), then clause (iii) shall apply;
and 
 (iii) Manufacturer’s President and Senior Vice President, Manufacturing and Product Development of Santarus shall
meet within five (5) days of the Stage 2 Failure in order to establish a Remediation Plan. 
 If the Remediation Plan is either not
mutually agreed upon or is not, in the reasonable judgment of Santarus, implemented satisfactorily, then Manufacturer shall be deemed to be in material breach of its obligations hereunder and will be formally notified in writing of such status by
the appropriate Santarus personnel. The Parties may mutually agree in writing to extend any of the time periods referenced in this Section 2.8. 

2.9 STORAGE OF FINISHED PRODUCT. Until Finished Product is shipped, Manufacturer shall store all Finished Product identifiably distinct from
any other raw material and finished or filled product stocks and shall comply with all storage requirements set forth in the Specifications. 

Manufacturer shall assume responsibility for any loss or damage to such Finished Product while stored by Manufacturer. 

2.10 MULTI-COUNTRY PACKAGING REQUIREMENTS. If and when Santarus decides that it wishes to have Manufacturer manufacture the Finished Product
for countries in addition to the Territory, then Santarus shall inform Manufacturer of the packaging requirements for each new country and Manufacturer shall prepare a quotation for consideration by Santarus of the additional Raw Material costs, if
any, and the Price for the Finished Product destined for such new country. The agreed additional packaging requirements and related packaging costs and Price shall be set out in a written amendment to this Agreement or otherwise recorded in a
writing signed by the Parties. 
 2.11 API YIELD. 

2.11.1 Manufacturer shall promptly (and in any event no later than two (2) Business Days after Santarus’ request) provide an
inventory status report to Santarus from time to time as reasonably requested by Santarus. In addition, Manufacturer shall monitor on a monthly basis the inventory of Bulk API held by Manufacturer and Manufacturer shall provide Santarus with a
monthly inventory report (within five (5) Business Days following the last day of the applicable month) of the Bulk API held by Manufacturer, which shall contain the following information for such month: 

QUANTITY RECEIVED: The total quantity of Bulk API that complies with the Specifications and is received at the Facility during the applicable
period. 

  
 8 

 QUANTITY DISPENSED: The total quantity of Bulk API dispensed at the Facility during the
applicable period. The Quantity Dispensed is calculated by adding the Quantity Received to the inventory of Bulk API that complies with the Specifications and is held at the beginning of the applicable period, less the inventory of Bulk API that
complies with the Specifications and is held at the end of such period. The Quantity Dispensed shall only include Bulk API received and dispensed in connection with commercial manufacturing of Finished Product and, for certainty, shall not include
any Bulk API received or dispensed in connection with technical transfer activities or development activities during the applicable period, including, without limitation, any regulatory, stability, validation or test batches manufactured during the
applicable period. 
 QUANTITY CONVERTED: The total amount of Bulk API contained in the Finished Products produced with the Quantity
Dispensed, delivered by Manufacturer, and not rejected or returned in accordance with Section 3.5 or recalled under Article 5 as a result of a failure by Manufacturer to manufacture Finished Product that conforms to the Manufacturer
Manufacturing Responsibilities. 
 2.11.2 In addition, Manufacturer shall reconcile the inventory of Bulk API held by Manufacturer on a
[***] basis and shall provide a report to Santarus concerning such reconciliation within ten (10) days following the end of the applicable [***]. Within [***] days of the end of each six (6) month period after the Commencement of
Commercial Manufacturing, Manufacturer shall calculate the “ACTUAL SIX-MONTH YIELD” or “ASY” for the Finished Product during the six-month period, which ASY is the percentage of the Quantity Dispensed that was converted to
Finished Products and is calculated as follows: 
 Quantity Converted during the six-month period 

Quantity Dispensed during the six-month period 

2.11.3 After Manufacturer has produced a minimum of [***] batches of Finished Product and has produced batches for at least [***] months
pursuant to this Agreement, the Parties will mutually agree on the target yield (each, a “TARGET YIELD”). Thereafter, Manufacturer shall strive to maintain Actual Six-Month Yield levels for each Finished Product above the applicable Target
Yield. If the Actual Six-Month Yield falls below the respective Target Yield in any six month period, then Manufacturer shall reimburse Santarus for the cost of the shortfall based on the following calculation: 

[***] 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 9 

 2.11.4 Manufacturer shall notify Santarus in writing in the event that an amount in excess of
[***] kilograms of Bulk API is damaged, lost or otherwise rendered unusable (including to the extent contained in any non-conforming Finished Product) at any one time (a “Significant API Loss”) as soon as practicable following such
incident. In addition, and notwithstanding any provision in this Section 2.11 to the contrary, Manufacturer shall reimburse Santarus for such Bulk API within [***] days after discovery of the Significant API Loss. 

2.11.5 For the purposes of clarity, any Bulk API damaged, lost or otherwise rendered unusable in connection with the Significant API Loss
shall be included in the calculation of the Quantity Dispensed and any amount paid by Manufacturer in accordance with subsection 2.11.4 shall be credited against the amount, if any, to be paid by Manufacturer to Santarus pursuant to subsection
2.11.3. 
 2.12 COOPERATION AND QUARTERLY REVIEW. Each Party shall forthwith upon execution of this Agreement designate those of its
employees to be part of the team responsible for managing the relationship between the parties (the “RELATIONSHIP TEAM”). The Relationship Team from each Party shall meet in person or by telephone or video conference not less than
quarterly to review the current status of the business relationship (including performance against the KPIs as well as any additional manufacturing performance indicators established by the Parites) and address any issues that have arisen. 

ARTICLE 3 
 STANDARDS OF
MANUFACTURE 
 3.1 FINISHED PRODUCT. Manufacturer hereby warrants and covenants that all Finished Product manufactured and supplied to
Santarus under this Agreement: (a) shall have been manufactured, packaged, tested and stored in compliance with the Specifications, GMP, Applicable Laws and the terms and conditions of this Agreement and the Quality Agreement; (b) shall
not be adulterated, or misbranded within the meaning of the FFDCA or other Applicable Laws as of the time that the Finished Product is transferred to the carrier at Manufacturer’s shipping point; and (c) will have been shipped to Santarus
not later than [***]days after the date of the product blend manufacture (unless any delay in shipment beyond such [***] day period is due solely to a delay by Santarus in conducting its review for the final release of the Finished Product). The
foregoing obligations are referred to in this Agreement as the “MANUFACTURER MANUFACTURING RESPONSIBILITIES.” 
 3.2 MANUFACTURING
FACILITY. Manufacturer will manufacture Finished Product at the Facility. Manufacturer shall not manufacture any Finished Product in any other facility without first obtaining Santarus’ prior written consent. 

3.3 TESTING AND RELEASE BY MANUFACTURER. Manufacturer shall conduct chemical identity testing for all Bulk API received at the Facility within
[***] days of such receipt. Further, Manufacturer shall conduct full release testing of all Bulk API received at the Facility not later than [***] months after the date of receipt in accordance with the

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 10 

 
procedures and using the analytical testing methodologies set forth in the Specifications and the Quality Agreement. Manufacturer shall promptly (and in any event within five (5) days
following completion of the applicable testing) notify Santarus in writing of any failure of the Bulk API to conform to the Specifications for same, and any other problem it may identify with the Bulk API detected during the inspection and testing
process. Prior to shipping (or temporarily storing, if requested by Santarus) any order, Manufacturer shall test each batch of Finished Product manufactured under this Agreement, and Raw Materials used for such batch, for conformity with the
Specifications. Manufacturer shall conduct all such testing in accordance with the procedures and using the analytical testing methodologies set forth in the Specifications and the Quality Agreement. Manufacturer shall retain sufficient quantities
of all shipped Finished Product, Bulk API and Raw Materials to perform at least full duplicate quality control testing. Retained repository samples of all shipped Finished Product, Bulk API and Raw Materials shall be maintained in a suitable storage
facility until one (1) year after expiry or such longer period as may be required by Applicable Laws. All such samples shall be available for inspection and testing by Santarus at reasonable intervals upon reasonable notice. Santarus shall be
responsible, at all times, for the final release of the Finished Product, and Manufacturer shall not ship any Finished Product until Santarus has completed its final release. Upon prior written consent from Santarus, Manufacturer may arrange for
subcontractors to perform specific testing services for Raw Materials arising under this Agreement; provided that (a) all such subcontractors shall be duly qualified by Manufacturer under GMP and Applicable Laws to perform such testing;
(b) Manufacturer shall at all times remain fully responsible to Santarus for the performance of all obligations hereunder related to such subcontracted testing services; and (c) no subcontractors shall be utilized in connection with
release testing of the Finished Product. 
 3.4 STABILITY STUDIES. Manufacturer shall conduct stability studies on the Finished Products
according to the Specifications therefor, as required by the FDA or Foreign Regulatory Authorities as advised by Santarus or as requested by Santarus, and in any case on at least one batch of Finished Product from the Facility at least once per
calendar year following Commencement of Commercial Manufacturing or more frequently as may be specified in the Quality Agreement. Manufacturer shall provide to Santarus a report of all results and data obtained from such stability studies annually
or more frequently as may be specified in the Quality Agreement. Santarus will reimburse Manufacturer for the execution of the requested stability studies and the preparation of reports based upon a mutually agreed upon (in writing) cost schedule.

 3.5 ACCEPTANCE PROCEDURES. 

3.5.1 Finished Product Claims. Santarus has the right to reject any portion of any shipment of Finished Products that deviates from the
Manufacturer Manufacturing Responsibilities, without invalidating any remainder of such shipment. Santarus or its agent shall visually inspect the Finished Products manufactured by Manufacturer upon receipt thereof and shall give Manufacturer
written notice (a “DEFICIENCY NOTICE”) of all claims for Finished Products that deviate from the Manufacturer Manufacturing Responsibilities within [***] days after Santarus’ receipt thereof (or, in the case of any defects not
reasonably 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 11 

 
susceptible to discovery upon receipt by visual inspection of the Finished Product, including those requiring laboratory analysis, within [***] days after discovery thereof by Santarus). Should
Santarus fail to provide Manufacturer with the Deficiency Notice within the applicable [***] -day period, then the delivery shall be deemed to have been accepted by Santarus on the [***] day after delivery or discovery, as applicable. 

3.5.2 Determination of Deficiency. Upon receipt of a Deficiency Notice, Manufacturer shall have [***] to advise Santarus by notice in writing
that it disagrees with the contents of such Deficiency Notice. If Santarus and Manufacturer fail to agree within [***] after the Santarus’ receipt of Manufacturer’s notice as to whether any Finished Products identified in the Deficiency
Notice deviate from the Manufacturer Manufacturing Responsibilities, then the Parties shall mutually select an independent laboratory to evaluate if the Finished Products deviate from the Manufacturer Manufacturing Responsibilities. Such evaluation
shall be binding on the Parties, and if such evaluation certifies that any Finished Products deviate from the Manufacturer Manufacturing Responsibilities, Santarus may reject those Finished Products in the manner contemplated in this
Section 3.5. If such evaluation does not so certify in respect of any such Finished Products, then Santarus shall be deemed to have accepted delivery of such Finished Products on the [***] day after delivery (or, in the case of any defects not
reasonably susceptible to discovery upon receipt by visual inspection of the Finished Product, including those requiring laboratory analysis, on the [***] day after discovery thereof by Santarus). The expenses of such testing shall be borne by
Manufacturer if the non-conformity with the Manufacturer Manufacturing Responsibilities is confirmed, and otherwise by Santarus. 
 3.5.3
Manufacturer Responsibility. In the event Santarus rejects Finished Products in accordance with this Section 3.5 and the rejected Finished Product is determined not to conform to the Manufacturer Manufacturing Responsibilities, Manufacturer
will credit Santarus’ account for Manufacturer’s invoice price to Santarus for such non-conforming Finished Products. If Santarus shall have previously paid for such defective Finished Products, Manufacturer shall promptly, at
Santarus’ election, either: (i) refund the invoice price for such defective Finished Products; (ii) offset such amount against other amounts due to Manufacturer hereunder; or (iii) use its best efforts to replace such Finished
Products with conforming Finished Products as soon as reasonably possible without Santarus being liable for payment therefor under Section 6.3. Further, Manufacturer shall reimburse Santarus for all reasonable shipping, handling and storage
charges incurred in association with such non-conforming Finished Product and for the Bulk API utilized in such non-conforming Finished Product in accordance with Section 2.11. Nothing in this Section 3.5.3 shall be construed to limit the
rights and remedies available to Santarus at law or in equity. 
 3.6 SPECIFICATION AMENDMENTS. 

3.6.1 Cooperation. Subject to Section 3.6.4, the Parties shall cooperate with each other to amend or supplement the Specifications to the
extent necessary to comply with changes in GMP, Applicable Laws or other requirements of Government Authorities. If an amendment to the Specifications requires FDA approval and/or the approval of a Foreign

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 12 

 
Regulatory Authority, Manufacturer shall not implement such change unless and until the necessary approval has been obtained by Santarus in writing. In no event shall Manufacturer implement any
other modification or addition to the Specifications, including without limitation, changes in raw materials, equipment or methods of production or testing for the Finished Product, without the prior written consent of Santarus, which consent may be
withheld for any or no reason. 
 3.6.2 Santarus’ Request for Change. Subject to Section 3.6.4, Santarus shall have the right to
amend the Specifications from time to time. 
 3.6.3 Manufacturer’s Request for Change. Subject to Section 3.6.4, if Manufacturer
wishes to make any change to the Specifications, Manufacturer shall notify Santarus, and such notice shall describe the proposed change and the impact of such change on the manufacturing process, including details of any changes in manufacturing
costs. Santarus may accept or reject, in its sole and absolute discretion, any such change proposed by Manufacturer. 
 3.6.4 Price
Adjustments. Amendments to the Specifications or the Quality Agreement requested by Santarus will only be implemented following a technical and cost review in good faith by Manufacturer and are subject to Santarus and Manufacturer reaching agreement
as to revisions, if any, to the Price specified in Exhibit B necessitated by any such amendment. If Santarus accepts a proposed Price change, the proposed change in the Specifications shall be implemented, and the Price change shall become effective
only with respect to those orders of Finished Products that are manufactured in accordance with the revised Specifications. 
 3.7 RECORDS.
Manufacturer shall maintain all records necessary to comply with all GMP and Applicable Laws relating to the manufacture, packaging, testing, storage and shipment of Finished Product. All such records shall be maintained for such period as may be
required by Applicable Laws; provided, however, that all records relating to the manufacture, stability and quality control of each batch of Finished Product shall be retained until the Parties agree in writing to dispose of such records. 

3.8 AUDIT. Upon reasonable prior notice and at reasonable intervals, Manufacturer shall allow Santarus and its representatives to inspect
Manufacturer’s books and records relating to the manufacture of the Finished Product and permit Santarus to access Manufacturer’s facilities used to manufacture the Finished Product for the purposes of (a) making quality assurance
audits of the facilities and of the procedures and processes used by Manufacturer in manufacturing, packaging, testing, storing and shipping Finished Product, and (b) confirming Manufacturer’s compliance with this Agreement, provided that
a Manufacturer representative is present during any such inspection. Santarus, or its representative(s), shall conduct such audit during normal business hours at a time on which the Parties have mutually agreed, and in such a manner that does not
unreasonably interfere with Manufacturer’s normal business activities. 

  
 13 

 ARTICLE 4 

REGULATORY MATTERS AND QUALITY CONTROL 

4.1 COMPLIANCE BY MANUFACTURER. Manufacturer shall remain in compliance with all Applicable Laws, including GMP, at all times during the Term
and, without limiting the generality of the foregoing, maintain a quality control program consistent with GMP as required by the FDA, and to the extent the parties have reached agreement pursuant to Section 2.10 with respect to countries in
addition to the Territory, the applicable Foreign Regulatory Authorities. 
 4.2 SANTARUS’ REGULATORY RESPONSIBILITY. Santarus shall be
responsible for obtaining and maintaining all regulatory filings and approvals (excluding the overall licensure and permitting of the Facility) for the manufacture and marketing of the Finished Product, including without limitation all INDA’s
and NDA’s for the Finished Product. Santarus shall control and own all such filings and approvals. Manufacturer will supply to Santarus from time to time, all such data relating to the Finished Product, including release test results, complaint
test results, all investigations (in manufacturing, testing and storage), and the like, that Santarus reasonably requires in order to complete any such filing or approval, including any annual product review report that Santarus is required to file
with the FDA and as provided in the Quality Agreement. At Santarus’ request, Manufacturer may prepare annual product review reports on behalf of Santarus and in accordance with Santarus’ instructions. Santarus will compensate Manufacturer
for the preparation of annual product review reports based upon a mutually agreed upon (in writing) cost schedule. 
 4.3 MANUFACTURING
PROCESS. If any process event occurs during the manufacturing of any Finished Product, which event is likely materially to affect the safety, efficacy or regulatory status of the Finished Product, then Manufacturer shall promptly notify Santarus.
Further, Manufacturer shall fully and appropriately investigate and report to Santarus on all complaints and notices of quality issues concerning the Finished Products from the FDA, any Foreign Regulatory Authority or Government Authority of which
Santarus shall have given Manufacturer notice. Santarus and Manufacturer shall consult with each other as to the disposition of all affected batches of such Finished Product. Manufacturer shall report to Santarus in writing any other atypical
process event that is unlikely to materially affect the safety, efficacy or regulatory status of the Finished Product within a reasonable time after occurrence. No Bulk API or Finished Product may be reprocessed without the prior written consent of
Santarus. 
 4.4 COMMUNICATIONS. Each party may communicate with the FDA or any Foreign Regulatory Authority or Government Authority
regarding the Finished Products if such communication is necessary to comply with the terms of this Agreement or the requirements of any Applicable Law, governmental order or regulation; provided, however, in the event such requirement applies to
Manufacturer, Manufacturer shall notify Santarus in writing of the requirement and pending communication and, unless there is a legal prohibition against doing so, Manufacturer shall permit Santarus to accompany Manufacturer and take part in any
communications with the FDA or any Foreign Regulatory Authority or Government Authority, and to receive copies of all such communications to and from the FDA or any Foreign Regulatory Authority or Government Authority. 

  
 14 

 4.5 GOVERNMENT INSPECTION. 

4.5.1 Manufacturer shall make its internal practices, books and records relating to its manufacture of the Finished Product available and
allow access to all facilities used for manufacturing the Finished Product to the FDA, any Foreign Regulatory Authority and any other Government Authority having jurisdiction over the manufacture of the Finished Product for the purposes of
determining Manufacturer’s compliance with GMP and Applicable Laws. 
 4.5.2 Manufacturer agrees to advise Santarus by telephone and
facsimile immediately of any proposed or announced visit or inspection (and shall permit Santarus to be onsite at any such visit or inspection), and as soon as possible but in any case on the same business day of any unannounced visit or inspection,
by the FDA, any Foreign Regulatory Authority or any other Government Authority relating to the Finished Product. Manufacturer shall provide Santarus with a reasonable description in writing of each such visit or inspection promptly (but in no event
later than five (5) calendar days) thereafter, and with copies of any letters, reports or other documents (including form 483’s) issued by any such authorities that relate to the Finished Product. Santarus may review Manufacturer’s
responses to any such reports and communications, and Santarus’ comments and suggestions shall be incorporated into such response. 

4.5.3 If the FDA or any other Foreign Regulatory Authority or any other Government Authority conducts an inspection of the Facility in
circumstances that are not related to the manufacturing of the Finished Product (as contemplated by subsection 4.5.2 above) and issues a 483 observation, inspection report or other formal or informal document in respect of such inspection which
questions Manufacturer’s compliance with critical or major GMP standards relating to operations at the Facility which is otherwise could have an adverse impact on the Finished Product then Manufacturer shall notify Santarus promptly (but in no
event later than five (5) calendar days) after Manufacturer receives a written copy of such observation, report or document. 
 4.5.4
Manufacturer shall keep Santarus informed of (i) the remediation plan Manufacturer adopts to alleviate any concerns raised by the FDA or any other Foreign Regulatory Authority contemplated by Sections 4.5.2 or 4.5.3, (ii) progress in
implementing the remediation plan and (iii) the formal responses of the FDA or applicable Foreign Regulatory Authority to such remediation plan and its implementation. 

4.6 ENVIRONMENTAL AND OTHER LAWS AND REGULATIONS. In carrying out its obligations under this Agreement, Manufacturer shall comply with all
applicable environmental and health and safety laws (current or as amended or added), and shall be solely responsible for determining how to comply with same in carrying out these obligations. Notwithstanding the foregoing, nothing provided to
Manufacturer by Santarus, by way of materials, specifications, processing information or otherwise, is meant to diminish Manufacturer’s responsibility for such compliance. Manufacturer shall obtain and maintain all necessary licenses, permits
and governmental approvals (except for product-related Regulatory Approvals such as NDA’s) required to perform its manufacturing and supply services hereunder, including licensure and permitting of its manufacturing facilities by the FDA and
Foreign Regulatory Authorities. Manufacturer shall promptly notify Santarus of any circumstances, 

  
 15 

 
including the receipt of any notice, warning, citation, finding, report or service of process or the occurrence of any release, spill, upset, or discharge of hazardous substances (as may be
defined under Applicable Laws) relating to Manufacturer’s compliance with this Section 4.6 and which relates to the manufacture of Finished Product. Santarus reserves the right to conduct an environmental inspection of the Facility, at
reasonable intervals during normal business hours and with reasonable advance notice, for the purpose of determining compliance with this Section 4.6. Such inspection shall not relieve Manufacturer of its obligation to comply with all
applicable environmental and health and safety laws and does not constitute a waiver of any right otherwise available to Santarus. 
 4.7
END-USER INQUIRIES AND COMPLAINTS. Subject to Manufacturer’s obligation to report certain information on a more expedited basis in respect of Adverse Experiences as described in Section 5.1 below, Manufacturer shall notify and refer to
Santarus, within three (3) Business Days after receipt, all communications from end-users of the Finished Product, including without limitation, inquiries regarding the Finished Product and its uses, and complaints, comments and suggestions
regarding the Finished Product and its effects on users. Santarus shall have the sole right to respond to all such communications and Manufacturer shall provide to Santarus reasonable cooperation and assistance in effecting such responses. 

ARTICLE 5 
 ADVERSE
EVENTS; RECALL 
 5.1 ADVERSE EXPERIENCE REPORTING. Manufacturer shall notify Santarus promptly and not later than twenty-four
(24) hours after it becomes aware of (a) any information concerning any potentially serious or unexpected side effect, injury, toxicity or sensitivity reaction or any unexpected incidence or other adverse experience (an “ADVERSE
EXPERIENCE”) and the severity thereof associated with the use of the Finished Product, whether or not determined to be attributable to the Finished Product; or (b) any information regarding any pending or threatened action which may affect
the safety or efficacy claims of the Finished Product or the continued marketing of the Finished Product in any nation or jurisdiction. Further and without limiting the foregoing, Manufacturer shall notify Santarus by telephone and facsimile within
twenty-four (24) hours after Manufacturer first becomes aware of any serious Adverse Experience that gives cause for concern or is unexpected or that is fatal, life-threatening (as it occurred), permanently disabling, requires (or prolongs)
inpatient hospitalization, represents a significant hazard, or is a cancer or a congenital anomaly or represents an overdose, or any other circumstance that might necessitate a recall, expedited notification of FDA or any other relevant Government
Authorities or a significant change in the label of the Finished Product, including, without limitation, information concerning any incident that causes Finished Product shipped to Santarus or its labeling to be mistaken for or, applied to, another
product, information concerning any bacteriological contamination, or any significant chemical, physical, or other change or deterioration in the Finished Product shipped to Santarus, or any failure of one or more batches of Finished Product shipped
to Santarus to meet Specifications or to conform with Applicable Laws, and any deviation from the specified environmental conditions for shipping or storage of the Finished Product. To the extent that Santarus becomes aware of any Adverse Experience
that appears to be related to the manufacture of Finished Product, Santarus shall notify Manufacturer promptly and not later than twenty-four (24) hours after Santarus becomes aware of such Adverse Experience. In connection with any

  
 16 

 
such Adverse Experience, each Party shall make such reports as are necessary to comply with Applicable Laws, at its sole expense. Further, in the event a Party (or its Affiliates) receives a
communication or directive from a Government Authority commencing or threatening seizure of Finished Product, or other removal from the market of Finished Product, such Party shall transmit such information to the other Party within twenty-four
(24) hours of receipt. 
 5.2 NOTIFICATION AND RECALL. The handling of recalls and withdrawals of Finished Products shall be within the
sole discretion of Santarus, unless otherwise required by Applicable Laws. If any Government Authority issues or requests a recall or takes similar action in connection with Finished Product, or if Santarus determines that an event, incident or
circumstance has occurred which may reasonably result in the need for a recall or market withdrawal (collectively, “RECALLS”), Santarus shall, within twenty four (24) hours, advise Manufacturer thereof by telephone or facsimile, after
which the Parties shall promptly discuss and work together to effect an appropriate course of action. Notification to FDA (or such other Foreign Regulatory Authority or Government Authority) and conducting such Recall shall be the responsibility of
Santarus. Manufacturer shall (a) cooperate fully with Santarus in the event of any such Recall, withdrawal and/or related disposition of any affected Finished Products in Manufacturer’s possession and (b) provide such assistance in
connection therewith as Santarus may reasonably request. 
 5.3 RECALL EXPENSE. [***] Nothing in this Section 5.3 shall be construed to
limit the rights and remedies available to Santarus at law or in equity. 
 ARTICLE 6 

COMPENSATION; PAYMENT 
 6.1
PRICE OF FINISHED PRODUCT. The Price includes all Raw Materials, manufacturing, packaging, testing and temporary storing costs associated with manufacturing and supplying the Finished Product, and includes the costs of such quality control measures
as required by the Specifications and the Quality Agreement. The cost of the Bulk API shall form no part of the Price. The costs of shipping, handling, insurance and freight will be borne by Santarus and form no part of the Price. 

6.2 CHANGES IN PRICE OF FINISHED PRODUCT. [***] 

In connection with a Price review pursuant to clause (a) of this Section 6.2, Manufacturer shall deliver to Santarus reasonably
detailed documentation concerning increases or decreases in the cost of Raw Materials or Manufacturer’s cost of manufacturing to facilitate the discussion. In connection with all fee adjustment requests pursuant to clause (b) of this
Section 6.2, Manufacturer shall deliver to Santarus a revised Exhibit B and such budgetary pricing information or other documentation reasonably sufficient to demonstrate that a Price adjustment is justified. Each of Santarus and Manufacturer
shall forthwith use all reasonable efforts to agree on a revised Price in respect of each affected Finished Product. In the event the Parties are unable to reach agreement concerning adjustments to the Price, such dispute shall be resolved in
accordance with Article 13. Until such time as dispute is resolved the price per Finished Product shall be the most current mutually agreed upon Price. 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 17 

 6.3 PAYMENT TERMS. Santarus shall pay Manufacturer for the Finished Product shipped to Santarus
within [***] pursuant to Section 2.6. Manufacturer shall send all invoices by email or facsimile to the email address or facsimile number of the accounts payable personnel designated by Santarus from time to time. All invoices shall be dated as
of the date of the email or facsimile as noted in the foregoing sentence, and not any earlier date. Manufacturer’s invoice shall reference the Purchase Order number and be sent to the “Bill to” address of Santarus specified on the
Purchase Order, and Manufacturer’s packing list must reference the Purchase Order number and be sent to the applicable “Ship to” address on the Purchase Order. Santarus may withhold a portion of any invoice that it disputes in good
faith pending resolution of such dispute. 
 6.4 FORM OF PAYMENT. Each Party shall make all payments due the other Party under this
Agreement in U.S. Dollars by check made payable to the order of the other Party or by wire transfer of immediately available funds to such account notified by the receiving Party from time to time to the other Party in writing. 

6.5 INTENTIONALLY OMITTED. 
 6.6
DISPUTED INVOICES. In the event that Santarus disputes any amounts under any invoice for Finished Product supplied by Manufacturer, such dispute shall be resolved in accordance with Section 3.5 (with respect to non-conformance of Finished
Product) or otherwise under Article 13. Pending resolution of such dispute, Santarus shall be obligated to pay any amounts under such invoice that are not in dispute. Upon resolution of any such dispute in favor of Manufacturer, Santarus shall pay
all remaining amounts owing under such invoice within [***] Business Days after such resolution. 
 ARTICLE 7 

RAW MATERIALS 
 7.1
PURCHASE OF RAW MATERIALS. Except for the Bulk API which will be supplied to Manufacturer by Santarus, Manufacturer shall purchase all packaging components (including labels, product inserts and other labeling for the Finished Product), raw
materials and other ingredients for the manufacture of the Finished Product (collectively, “RAW MATERIALS”). Any obligation that Santarus may have under this Agreement to purchase or reimburse Manufacturer for expired or obsolete Raw
Materials shall in no event extend beyond a [***] month supply of such Raw Materials based on the most recent Forecast. Manufacturer shall utilize and manufacture all Raw Materials and Bulk API on a first-in, first-out basis. 

7.2 STORAGE OF BULK API AND RAW MATERIALS. Manufacturer shall store the Bulk API and Raw Materials at Manufacturer’s storage facility at
the Facility with due care and attention to the requirements set forth in the Specifications and in accordance with GMP and 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 18 

 
Applicable Laws so as to protect such materials from loss or damage. While the Bulk API and the Raw Materials are in storage, Manufacturer shall assume the risk of loss or damage to such
materials from any cause whatsoever. Manufacturer shall ensure that, while such Bulk API is in storage, such materials do not become subject to any lien or other security interest securing any obligation owed or alleged to be owed by Manufacturer to
any person or entity. 
 7.3 SANTARUS’ RESPONSIBILITY FOR COST OF RAW MATERIALS. If Raw Materials become obsolete or otherwise no
longer useable in the manufacturing process for the Finished Product because (a) Santarus deviated from the Forecast, or (b) the Specifications have been changed pursuant to Section 3.6, Manufacturer shall use its commercially
reasonable efforts to cover the cost of excess Raw Materials by: (i) returning such Raw Materials to the vendor, (ii) selling such Raw Materials, (iii) utilizing such Raw Materials in manufacturing products for its other customers to
the extent possible, and (iv) implementing other measures to mitigate the loss due to such excess Raw Materials. To the extent that Manufacturer is unable to off-set such loss fully, Santarus shall reimburse Manufacturer for such Raw Materials
but solely to the extent actually incurred by Manufacturer and in no event beyond the limit of liability set forth in Section 7.1. 

7.4 MANUFACTURER’S RESPONSIBILITY FOR COST OF RAW MATERIALS. In the event Raw Materials expire or become obsolete or no longer useable in
the manufacturing process for the Finished Product because (a) Manufacturer failed to manufacture and supply the quantities ordered by Santarus pursuant to a Purchase Order, (b) quantities of such Raw Materials are in excess of the limits
of Santarus’ liability set forth in Section 7.1, or (c) Manufacturer failed to store Raw Materials as required by the applicable Specifications or under Section 7.2, then Manufacturer shall bear all responsibility for the cost of
such Raw Materials. 
 ARTICLE 8  

CONFIDENTIALITY 
 8.1
CONFIDENTIALITY; EXCEPTIONS. The Parties agree that, for the Term and for [***] thereafter (other than for trade secrets, for which the confidentiality obligations set forth herein shall last as long as trade secret law shall allow), all non-public,
proprietary or “confidential” disclosures, know-how, data, and technical, financial and other information of any nature whatsoever (collectively, “CONFIDENTIAL INFORMATION”), disclosed or submitted, either orally or in writing
(including, without limitation, by electronic means) or through observation, by one Party (the “DISCLOSING PARTY”) to the other Party (the “RECEIVING PARTY”) hereunder, including, without limitation, the terms of this Agreement,
shall be received and maintained by the Receiving Party in strict confidence, shall not be used for any purpose other than the purposes expressly contemplated by this Agreement, and shall not be disclosed to any Third Party (including, without
limitation, in connection with any publications, presentations or other disclosures). Notwithstanding the foregoing, Santarus may disclose on a need-to-know basis the existence of this Agreement and the terms hereof to any bona fide potential
acquirers, corporate partners, investors or financial advisors. The Receiving Party will promptly notify the Disclosing Party upon discovery of any unauthorized use or disclosure of the Disclosing Party’s Confidential Information. Confidential
Information belongs to and shall remain the property of the Disclosing Party. 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 19 

 8.2 EXCEPTIONS. The provisions of this Article 8 shall not apply to any information of the
Disclosing Party which can be shown by competent evidence by the Receiving Party: 
 8.2.1 To have been known to or in the possession of the
Receiving Party prior to the date of its actual receipt from the Disclosing Party; 
 8.2.2 To be or to have become readily available to the
public other than through any act or omission of any Party in breach of any confidentiality obligations owed to the Disclosing Party; 

8.2.3 To have been disclosed to the Receiving Party, other than under an obligation of confidentiality, by a Third Party which had no
obligation to the Disclosing Party not to disclose such information to others; or 
 8.2.4 To have been subsequently independently developed
by the Receiving Party without use of or reference or access to the Disclosing Party’s Confidential Information. 
 8.3 AUTHORIZED
DISCLOSURE. The Receiving Party may disclose the Disclosing Party’s Confidential Information hereunder solely to the extent (a) approved by the Disclosing Party; or (b) the Receiving Party is legally required to disclose such
Confidential Information, provided, however, that prior to any such required disclosure, the Receiving Party will, except where impracticable, give reasonable advance notice to the Disclosing Party of such disclosure (so that the Disclosing Party
may seek a protective order and or other appropriate remedy or waive compliance with the confidentiality provisions of this Article) and will use its reasonable efforts to secure confidential treatment of such Confidential Information required to be
disclosed. 
 8.4 RETURN OF CONFIDENTIAL INFORMATION. The Receiving Party shall keep the Disclosing Party’s Confidential Information in
appropriately secure locations. Upon the expiration or termination of this Agreement or at any time upon the Disclosing Party’s request, the Receiving Party shall destroy or return to the Disclosing Party, at the Disclosing Party’s written
request, all Confidential Information belonging to the Disclosing Party possessed by the Receiving Party, or its officers, directors, employees, agents and consultants; provided however that a Receiving Party may retain one (1) copy of the
Disclosing Party’s Confidential Information in an appropriately secure location, which by Applicable Laws it must retain, for so long as such Applicable Laws require such retention but thereafter shall dispose of such retained Confidential
Information in accordance with Applicable Laws or this Section 8.4. 
 8.5 EQUITABLE RELIEF. The Receiving Party agrees that, due to
the unique nature of the Confidential Information, the unauthorized disclosure or use of the Confidential Information of the Disclosing Party may cause irreparable harm and significant injury to the Disclosing Party, the extent of which may be
difficult to ascertain and for which there may be no adequate remedy at law. Accordingly, the Receiving Party agrees that the Disclosing Party, in addition to any other available remedies, shall have the right to seek an immediate injunction and

  
 20 

 
other equitable relief enjoining any breach or threatened breach of this Agreement. The Receiving Party shall notify the Disclosing Party in writing immediately upon the Receiving Party’s
becoming aware of any such breach or threatened breach. 
 ARTICLE 9  

INTELLECTUAL PROPERTY MATTERS 

9.1 OWNERSHIP OF INTELLECTUAL PROPERTY. 

Manufacturer agrees that Santarus shall own all right, title and interest in and to all Inventions, and any intellectual property rights
(including patent rights and trade secret rights) therein, covering: 
 (a) Santarus’ Finished Product, the Specifications therefor and
the uses thereof; and 
 (b) any method of manufacture directly and solely related to the Finished Product, regardless of whether such
Invention was conceived, reduced to practice or created solely by employees or agents of Manufacturer or its Affiliates or jointly by the employees or agents of Santarus or its Affiliates with the employees or agents of Manufacturer or its
Affiliates (collectively, the “PRODUCT INVENTIONS”). As to all Inventions other than Product Inventions, including without limitation, those Inventions relating to manufacturing process innovations that are generally applicable to the
manufacture of drug compounds and not solely to the manufacture of the Finished Product (collectively, the “OTHER INVENTIONS”), the parties agree that the following shall apply: 

(i) All Other Inventions, which are conceived, reduced to practice, or created solely by employees or agents of Manufacturer or
its Affiliates in the course of performing the services under this Agreement (including any pre-existing technology of Manufacturer which Manufacturer so employs), shall be owned by Manufacturer. Manufacturer shall and hereby does grant to Santarus
and its Affiliates a perpetual, royalty-free, exclusive, worldwide, irrevocable license, to use and practice all such Manufacturer-owned Other Inventions to manufacture and have manufactured the Finished Products and to use, import, offer to sell,
and sell the same, with full right to sublicense to any Third Party in connection with the manufacture, sale or distribution of the Finished Product. 

(ii) All Other Inventions which are conceived, reduced to practice, or created by employees or agents of Santarus or its
Affiliates (including any pre-existing technology of Santarus which Santarus shares with Manufacturer hereunder), shall be owned by Santarus. Santarus shall and hereby does grant to Manufacturer and its Affiliates a royalty-free, non-exclusive
license during the Term, without the right to sublicense, to use and practice all such Santarus-owned Other Inventions solely to manufacture the Finished Products hereunder. 

(iii) All Other Inventions which are conceived, reduced to practice, or created jointly by: (i) employees or agents of
Santarus or its Affiliates; and by (ii) employees or agents of Manufacturer or its Affiliates, pursuant to this Agreement, shall 

  
 21 

 
be owned by Santarus, unless the parties have agreed in writing to a different arrangement in another consulting or services agreement which is more specific to the services provided by
Manufacturer in connection with such Other Invention. Santarus shall and hereby does grant to Manufacturer and its Affiliates a perpetual, royalty-free, non-exclusive, worldwide, irrevocable license to use and practice all such Santarus-owned Other
Inventions, with the right to sublicense to any Third Party. 
 9.2 ASSIGNMENT. Each Party agrees to disclose promptly in writing to the
other all Product Inventions and Other Inventions to be owned by the other pursuant to Section 9.1 and hereby irrevocably transfers, conveys and assigns, and agrees to transfer, convey and assign, to the other, its successors and assigns,
without reservation or additional consideration, all of its right, title and interest (anywhere in the world) in, to, and under the Product Inventions and Other Inventions, whether currently existing or created or developed later, including, without
limitation, all copyrights, trademarks, trade secrets, patent rights, industrial rights and all other intellectual property and proprietary rights related thereto, including all rights to protect, enforce (whether for past, present or future
infringement), defend and exploit such Product Inventions and Other Inventions and collect and retain all proceeds therefrom, effective immediately upon the inception, conception, creation or development thereof. 

9.3 ASSISTANCE. Each Party shall have the first right to file and prosecute patent applications in respect of those Inventions it is to own
pursuant to Section 9.1 and such Party shall be solely responsible for the costs of filing, prosecution and maintenance of such patents and patent applications. 

Each Party agrees to cooperate with the other or its designee(s), both during and after the Term, in applying for, obtaining, perfecting,
evidencing, sustaining and enforcing the other’s right, title and interest in and to the Product Inventions and Other Inventions, including, without limitation, executing such written instruments as may be prepared by the other and doing such
other acts as may be necessary in the opinion of the other to obtain a patent, register a copyright, or otherwise enforce the other’s rights in such Product Inventions and Other Inventions (and each Party hereby irrevocably appoints the other
and any of its officers and agents as its attorney in fact to act for and on the other’s behalf and instead of it, with the same legal force and effect as if executed by it). Each Party hereby represents, warrants, and covenants that all
employees, consultants and agents performing services for it hereunder have assigned in writing all of their right, title and interest in, to and under any and all Product Inventions and Other Inventions to such Party. All Product Inventions and
Other Inventions and embodiments thereof shall be deemed to be Confidential Information of the Party to own such Invention pursuant to Section 9.1, and the other Party shall be subject to the obligations of nonuse and nondisclosure under
Article 8 with respect thereto. 
 ARTICLE 10 

REPRESENTATIONS, WARRANTIES AND COVENANTS 

10.1 REPRESENTATIONS AND WARRANTIES OF THE PARTIES. Each Party represents, warrants and covenants to the other Party that: 

10.1.1 such Party is duly organized and validly existing and in good standing under the laws of the jurisdiction of its formation; 

  
 22 

 10.1.2 such Party has the full corporate power and is duly authorized to enter into, execute and
deliver this Agreement, and to carry out and otherwise perform its obligations thereunder; 
 10.1.3 this Agreement has been duly executed
and delivered by, and is a legal and valid obligation binding upon such Party and the entry into, the execution and delivery of, and the carrying out and other performance of its obligations under this Agreement by such Party (a) does not
conflict with, or contravene or constitute any default under, any agreement, instrument or understanding, oral or written, to which it is a party, including, without limitation, its certificate of incorporation or by-laws, and (b) does not
violate Applicable Law or any judgment, injunction, order or decree of any Government Authority having jurisdiction over it; and 
 10.1.4
in connection with its performance under this Agreement, it shall comply with all Applicable Laws. 
 10.2 ADDITIONAL REPRESENTATIONS,
WARRANTIES AND COVENANTS OF MANUFACTURER. In addition to representations and warranties set forth elsewhere in this Agreement, Manufacturer further represents, warrants to, and covenants with, Santarus that: 

10.2.1 At all times during the Term, all parts of the Facility that are directly associated with the testing and storage of the Bulk API and
Raw Materials and the manufacturing, packaging, testing and storage of the Finished Products shall remain in compliance with all Applicable Laws, and all other parts of the Facility shall remain, in all material respects, in compliance with all
Applicable Laws. 
 10.2.2 Manufacturer shall obtain and maintain all necessary licenses, permits or approvals required by Applicable Laws
in connection with the manufacture, packaging, testing and storage of the Finished Product, including, without limitation, permits related to manufacturing facilities; 

10.2.3 Manufacturer’s manufacturing facilities are in compliance with GMP; 

10.2.4 Manufacturer has disclosed to Santarus any and all form 483’s, warning letters or similar notices relating to its Facility and
import alerts for any other products manufactured in such Facility issued during the last five (5) years; 
 10.2.5 Title to all the
Finished Product sold hereunder, upon payment thereof by Santarus as provided herein, shall pass to Santarus free and clear of any security interest, lien or other encumbrance; 

10.2.6 Throughout the Term, Manufacturer has, and shall maintain, sufficient facilities, resources, and a work force suitably qualified and
trained to meet its obligations to supply the Finished Product to Santarus pursuant to this Agreement; 

  
 23 

 10.2.7 The contributions of Manufacturer to the manufacture of the Finished Product in accordance
with this Agreement do not infringe any Third Party rights (including, without limitation, any intellectual property rights) anywhere in the world; 

10.2.8 Manufacturer is not aware of any pending or threatened claims against Manufacturer asserting that any of the activities of Manufacturer
relating to the manufacture, import, use, or sale of pharmaceutical products, or the conduct of the activities contemplated herein by Santarus, infringe, misappropriate, or violate the rights of any Third Party; and 

10.2.9 Manufacturer shall ensure all employees, consultants, subcontractors and agents performing services for Manufacturer hereunder assign
in writing to Manufacturer all of their right, title and interest in, to and under any and all Inventions. 
 10.2.10 It nor any of its
employees, consultants, subcontractors and agents performing services for Manufacturer hereunder is (1) under investigation by the FDA for debarment action, (2) presently debarred under the regulations of the FDA, or (3) presently
debarred pursuant to the Generic Drug Enforcement Act of 1992 (21 U.S.C. ‘301 et seq.). 
 10.4 DISCLAIMER. EXCEPT AS EXPRESSLY SET
FORTH IN THIS AGREEMENT, THE PARTIES MAKE NO REPRESENTATIONS OR WARRANTIES OF ANY KIND WHATSOEVER, EITHER EXPRESS OR IMPLIED, WRITTEN OR ORAL, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY, WARRANTY OF FITNESS FOR A
PARTICULAR PURPOSE, OR WARRANTY OF NON-INFRINGEMENT. 
 ARTICLE 11 

TERM AND TERMINATION 
 11.1
TERM. This Agreement shall commence as of the Effective Date and shall continue in full force for a period of four (4) years from the Commencement of Commercial Manufacturing, unless earlier terminated in accordance with the terms and
conditions of this Article 11 (the “INITIAL TERM”). After the Initial Term, this Agreement shall continue in force for an indefinite duration (the “RENEWAL TERM”); provided that either Party may terminate this Agreement at any
time during the Renewal Term by providing the other Party with eighteen (18) months prior written notice of termination. 
 11.2
TERMINATION FOR CAUSE. In the event that either Party has failed to remedy a material breach of any of its representations, warranties or other obligations under this Agreement within [***] (the “REMEDIATION PERIOD”) following receipt of a
written notice thereof (the “Breach Notice”) from the other Party that expressly states that it is a notice under this Section 11.2, the non-breaching party may terminate this Agreement upon written notice to the other Party (the
“Termination Notice”). For the avoidance of doubt, a material breach of the Quality Agreement shall be deemed to be a breach of this Agreement for the purpose of determining the rights of the Parties to terminate this Agreement. 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 24 

 11.3 TERMINATION FOR BANKRUPTCY. Either Party may terminate this Agreement immediately if the
other Party becomes insolvent, makes a general assignment for the benefit of creditors, suffers or permits the appointment of a receiver for its business or assets, avails itself of or becomes subject to any petition or proceeding under any statute
of any state or country relating to insolvency or the protection of the rights of creditors. 
 11.4 REGULATORY PROCEEDINGS. Santarus may
terminate this Agreement effective immediately upon written notice to Manufacturer should the FDA or a Foreign Regulatory Authority having jurisdiction impose on the Facility an import ban in respect of the Finished Product or withdraw any license
required by Manufacturer to manufacture the Finished Product at the Facility or take other action that is reasonably likely to have a material adverse impact on Manufacturer’s ability to perform hereunder. 

11.5 GOVERNMENT ACTION. Santarus may terminate this Agreement effective immediately in the event that any governmental agency (including
without limitation, the FDA or a Foreign Regulatory Authority) takes any action, or raises any objection, that prevents Santarus from importing, exporting, purchasing, or selling the Finished Product or otherwise makes such activity unlawful. 

11.6 TERMINATION FOR DISCONTINUATION. Santarus may terminate this Agreement effective immediately if at any time it decides to no longer
market the Finished Product. 
 11.7 EFFECT OF TERMINATION. Except as otherwise provided in this Section 11.7 or elsewhere in this
Agreement, in the event this Agreement is terminated for any reason, (a) subject to Section 11.8, all rights and obligations of the Parties under this Agreement shall terminate; (b) Santarus shall surrender to Manufacturer, or, at
Manufacturer’s sole option and expense, Santarus shall destroy and provide Manufacturer with a certificate signed by a Responsible Executive of Santarus attesting to the destruction of, all copies of any Confidential Information of Manufacturer
in its possession (excluding all of the foregoing assigned to Santarus under Article 9 above); (c) Manufacturer shall surrender to Santarus, or, at Santarus’ sole option and expense, Manufacturer shall destroy and provide Santarus with a
certificate signed by a Responsible Executive of Manufacturer attesting to the destruction of, all copies of any Confidential Information provided by Santarus hereunder (except to the extent required to be maintained by Manufacturer pursuant to
Applicable Laws or this Agreement); (d) Santarus shall pay for any Finished Product manufactured at any time before the date of termination pursuant to any Purchase Order delivered to Manufacturer prior to such termination,
(e) Manufacturer shall return to Santarus all unused API and (f) Manufacturer shall implement the disposition of any unused Raw Material in accordance with Section 7.3 (including the option of being compensated for such as specified
in Section 7.3). Manufacturer shall cooperate with Santarus and assist in the transfer to Santarus of all legal and technical documents concerning API and Finished Products, including master batch records, validation reports, stability reports
and relevant manufacturer authorizations, existing retention samples and all such other documents and materials as may be reasonably necessary or useful for Santarus to source Finished Products from other qualified Third Parties. 

  
 25 

 11.8 ACCRUED RIGHTS. Termination, relinquishment, or expiration of this Agreement for any reason
shall be without prejudice to any right which shall have accrued to the benefit of either Party prior to such termination, relinquishment, or expiration. Such termination, relinquishment or expiration shall not relieve either Party from obligations
which are expressly indicated to survive termination or expiration of this Agreement. The provisions of this Article shall not limit or restrict the rights of any Party to seek remedies or take measures that may be otherwise available to it at law
or equity in connection with the enforcement and performance of obligations under this Agreement. Any provision of this Agreement intended by their specific terms or by necessary implication to survive the expiration or termination of this
Agreement, including without limitation, Articles, 8, 9, 12 and 13, shall so survive. 
 ARTICLE 12 

INDEMNIFICATION; INSURANCE 

12.1 INDEMNIFICATION BY SANTARUS. Santarus hereby agrees to defend, at its expense, indemnify, and hold harmless Manufacturer, its directors,
officers, employees, agents, and Affiliates, against all Third Party claims, demands, damages, liabilities, losses, costs and expenses, including, without limitation, attorney’s fees (collectively, “CLAIMS”) resulting from or arising
out of: (a) the negligence or willful misconduct of Santarus, its Affiliates, or their directors, officers, agents, employees or consultants in the performance of their obligations under this Agreement; (b) a material breach by Santarus of
any material provision of this Agreement; or (c) a breach by Santarus of any of its representations or warranties set forth in this Agreement; provided, however, that Santarus shall not be obligated to indemnify Manufacturer under this
Section 12.1 to the extent that such Claim results from or arises out of any act or omission for which Manufacturer is obligated to indemnify Santarus pursuant to Section 12.3 below. 

12.2 INDEMNIFICATION BY MANUFACTURER. Manufacturer hereby agrees to defend, at its expense, indemnify, and hold harmless Santarus, its
directors, officers, employees, agents, and Affiliates against all Third Party Claims resulting from or arising out of (a) the failure to manufacture, package and test the Finished Product in accordance with the Specifications, GMP, Applicable
Laws and the Manufacturer Manufacturing Responsibilities; (b) the failure to store the Finished Product, Bulk API or Raw Materials in accordance with the Specifications, GMP and Applicable Laws; (c) the negligence or willful misconduct of
Manufacturer, its Affiliates, or their directors, officers, agents, employees or consultants in the performance of their obligations under this Agreement, (d) a material breach by Manufacturer of any provision of this Agreement or the Quality
Agreement; or (e) a breach of any of Manufacturer’s representations, warranties, or covenants set forth in this Agreement or the Quality Agreement; provided, however, that Manufacturer shall not be obligated to indemnify Santarus under
this Section 12.3 to the extent that such Claim results from or arises out of any act or omission for which Santarus is obligated to indemnify Manufacturer pursuant to Sections 12.1 above. 

12.3 INDEMNIFICATION PROCEDURE. Each indemnified Party (the “INDEMNITEE”) agrees to give the indemnifying Party (the
“INDEMNITOR”) prompt written notice of any Claims or discovery of fact upon which the Indemnitee intends to base a request for indemnification. Notwithstanding the foregoing, the failure to give timely notice to the Indemnitor shall not
release the Indemnitor from any liability to the Indemnitee to the extent the Indemnitor is not materially prejudiced thereby. 

  
 26 

 12.3.1 The Indemnitee shall furnish promptly to the Indemnitor copies of all papers and official
documents in the Indemnitee’s possession or control which relate to any Claims; provided, however, that if the Indemnitee defends or participates in the defense of any Claims, then the Indemnitor shall also provide such papers and documents to
the Indemnitee. The Indemnitee shall reasonably cooperate with the Indemnitor in defending against any Claims. 
 12.3.2 The Indemnitor
shall have the right, by prompt written notice to the Indemnitee, to assume direction and control of the defense of any Claim, with counsel reasonably satisfactory to the Indemnitee and at the sole cost of the Indemnitor, so long as (a) the
Indemnitor shall promptly notify the Indemnitee in writing (but in no event more than thirty (30) days after the Indemnitor’s receipt of notice of the Claim) that the Indemnitor intends to indemnify the Indemnitee pursuant to this Article
absent the development of facts that give the Indemnitor the right to claim indemnification from the Indemnitee, and (b) the Indemnitor diligently pursues the defense of the Claim. 

12.3.3 If the Indemnitor assumes the defense of the Claim as provided in this Section 12.4, the Indemnitee may participate in such
defense with the Indemnitee’s own counsel who shall be retained, at the Indemnitee’s sole cost and expense; provided, however, that neither the Indemnitee nor the Indemnitor shall consent to the entry of any judgment or enter into any
settlement with respect to the Claim without the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed. If the Indemnitee withholds consent in respect of a judgment or settlement involving only the
payment of money by the Indemnitor and which would not involve any stipulation or admission of liability or result in the Indemnitee becoming subject to injunctive relief or other relief, the Indemnitor shall have the right, upon written notice to
the Indemnitee within five (5) days after receipt of the Indemnitee’s written denial of consent, to pay to the Indemnitee, or to a trust for its or the applicable Third Party’s benefit, such amount established by such judgment or
settlement in addition to all interest, costs or other charges relating thereto, together with all attorneys’ fees and expenses incurred to such date for which the Indemnitor is obligated under this Agreement, if any, at which time the
Indemnitor’s rights and obligations with respect to such Claim shall cease. 
 12.3.4 The Indemnitor shall not be liable for any
settlement or other disposition of a Claim by the Indemnitee which is reached without the written consent of the Indemnitor. 
 12.4
INSURANCE. Each Party shall maintain commercial general liability and product liability insurance through the term of this Agreement and for a period of five (5) years thereafter, which insurance shall afford limits of not less than
(i) [***] for each occurrence, and (ii) [***] annual aggregate. In addition, from time to time during the term of this Agreement, each Party shall increase their levels of insurance coverage if reasonably deemed prudent by such party in
light of the overall activities under this Agreement. If requested each Party will provide the other with a certificate of insurance evidencing the above and showing the name of the 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 27 

 
issuing company, the policy number, the effective date, the expiration date and the limits of liability. The insurance certificate shall further provide for a minimum of 30 days’ written
notice to the insured of a cancellation of, or material change in, the insurance. If a Party is unable to maintain the insurance policies required under this Agreement through no fault on the part of such Party, then such Party shall forthwith
notify the other Party in writing and the parties shall in good faith negotiate appropriate amendments to the insurance provision of this Agreement in order to provide adequate assurances. 

12.5 NO CONSEQUENTIAL DAMAGES. UNDER NO CIRCUMSTANCES SHALL EITHER PARTY BE RESPONSIBLE OR LIABLE TO THE OTHER PARTY FOR ANY INDIRECT,
INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, PUNITIVE OR OTHER LIKE DAMAGES, OR FOR ANY LOSS OF PROFITS, LOSS OF REVENUE, LOSS RESULTING FROM INTERRUPTION OF BUSINESS OR LOSS OF USE OR DATA , EVEN IF SUCH PARTY, OR ANY OF ITS DIRECTORS, OFFICERS,
EMPLOYEES, OR AGENTS HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES AND NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY OF ANY KIND, UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER THEORY, ARISING OUT OF OR
RELATING IN ANY WAY TO THIS AGREEMENT OR ITS IMPLEMENTATION. FOR THE AVOIDANCE OF DOUBT, NOTHING IN THIS SECTION 12.5 SHALL BE INTERPRETED TO LIMIT THE INDEMNIFICATION OBLIGATION OF EITHER PARTY IN CONNECTION WITH A PRODUCT LIABILITY CLAIM WITH
RESPECT TO THE CHARACTERIZATION OF DAMAGES OR LOSSES CLAIMED BY A THIRD PARTY AS BEING INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, PUNITIVE OR OTHER LIKE DAMAGES OR LOSSES. 

ARTICLE 13  
 GOVERNING
LAW; DISPUTE RESOLUTION 
 13.1 GOVERNING LAW. This Agreement shall be governed by and construed under the laws of the State of
California without giving effect to any choice of laws rule that would cause the application of the laws of any jurisdiction other than the internal laws of the State of California, to the rights and duties of the Parties. 

13.2 DISPUTE RESOLUTION/INJUNCTIVE RELIEF. Notwithstanding anything to the contrary contained in this Agreement, the parties specifically
agree to the following dispute resolution procedure. 
 13.2.1 Negotiation Between Responsible Executives. In the event of any dispute
between the Parties arising out of or related to this Agreement, the Parties shall refer such dispute to the Responsible Executive of Santarus and the Responsible Executive of Manufacturer for attempted resolution by good faith executive
negotiations within thirty (30) days after such referral is made. In the event such officers are unable to resolve such dispute within such thirty (30) day period, then the Parties will subject themselves to the arbitration procedures set
forth below before seeking any other means of resolving the dispute. 

  
 28 

 13.2.2 Arbitration. Any dispute arising out of or in connection with this Agreement including any
question regarding its existence, validity or termination, that can not be resolved through negotiation between Responsible Executives, shall be finally resolved by arbitration under the Rules of the American Arbitration Association. The arbitration
shall consist of a single arbitrator mutually agreed by the Parties, or, in the absence of such agreement, each Party shall select an arbitrator and those two arbitrators shall select a third arbitrator who shall arbitrate the dispute. Any
arbitration shall take place in San Diego, California, U.S.A. The award of the arbitrator shall be final and binding. The Parties waive any right to appeal the arbitration award, to the extent a right to appeal may be lawfully waived. Each Party
retains the right to seek judicial assistance: (a) to compel arbitration; (b) to obtain interim measures of protection pending or during arbitration; and (c) to enforce any decision of the arbitrator, including the final award. 

13.2.3 Exceptions. Notwithstanding the provision of this Section 13.2, the Parties agree that certain violations or threatened violations
of this Agreement will result in irrevocable harm to other Party, for which damages would be an inadequate remedy. In addition to any rights and remedies otherwise available, either Party, before or during arbitration, may apply to a court having
jurisdiction for a temporary restraining order, preliminary injunction or other interim or conservatory relief, where such relief is necessary to protect its interests pending completion of the arbitration proceedings without breach of this
arbitration agreement and without any abridgment of the powers of the arbitrators. 
 13.2.4 Continuation of Performance. Except where such
area of performance is the subject of dispute, each Party shall continue to perform its respective obligations under this Agreement while any dispute is being resolved in accordance with this Section 13.2 unless and until such obligations are
terminated or expire in accordance with the provisions of this Agreement. 
 ARTICLE 14 

RESOURCES 
 14.1
MANUFACTURING EQUIPMENT. Manufacturer shall be solely responsible for all costs associated with purchasing and maintaining the equipment, tools, technology, and all other items necessary to manufacture, package, test, store and ship the Finished
Product (“MANUFACTURING EQUIPMENT”). 
 14.3 PERSONNEL. Manufacturer shall be solely responsible for all costs associated with
hiring personnel to maintain the Manufacturing Equipment necessary to comply with its obligations pursuant to this Agreement. 
 ARTICLE
15  
 MISCELLANEOUS 

15.1 [***] 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 29 

 15.2 ASSIGNMENT. Manufacturer may not assign this Agreement or any of its rights or obligations
hereunder) without the written consent of Santarus, such consent not to be unreasonably withheld. 
 15.3 FORCE MAJEURE. With respect to
this Agreement, neither Party shall lose any rights hereunder or be liable to the other Party for damages or losses on account of failure of performance by the defaulting Party if the failure is occasioned by war, fire, explosion, flood, strike,
lockout, terrorist attacks, embargo, act of God, or any other similar cause to the extent beyond the reasonable control of the defaulting Party, provided that the Party claiming force majeure shall promptly notify the other Party in writing setting
forth the nature of such force majeure, shall use its best efforts to eliminate, remedy or overcome such force majeure and shall resume performance of its obligations hereunder as soon as reasonably practicable after such force majeure ceases.
Notwithstanding the previous sentence, if any force majeure continues for more than ninety (90) days, the other Party may terminate this Agreement. 

15.4 FURTHER ACTIONS. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be
necessary or appropriate in order to carry out the purpose and intent of this Agreement. 
 15.5 COMPLIANCE WITH LAWS. Each Party will
comply with all Applicable Laws in such Party’s exercise of its rights and performance of its obligations under this Agreement. 
 15.6
NOTICES. All notices required or permitted to be given under this Agreement shall be in writing and shall be deemed given if delivered personally or by facsimile transmission receipt verified, mailed by registered or certified mail return receipt
requested, postage prepaid, or sent by express courier service, to the Parties at the following addresses, or at such other address for a Party as shall be specified by like notice, provided that notices of a change of address shall be effective
only upon receipt thereof. 
 IF TO MANUFACTURER: MANUFACTURER 

OSG Norwich Pharmaceuticals Inc. 

6826 State Highway 12 
 Norwich,
New York 13815 
 Attention: President 

Fax: (607) 335-3100 
 IF TO
SANTARUS: SANTARUS, INC. 
 10590 West Ocean Air Drive, Suite 200 

San Diego CA 92130 
 Phone:
858-314-5700 
 Fax: 858-314-5701 

Attn: Senior Vice President, Manufacturing 

and Product Development 
 With a
copy to: SANTARUS, INC. 
 10590 West Ocean Air Drive, Suite 200 

San Diego CA 92130 
 Phone:
858-314-5700 
 Fax: 858-314-5701 

Attn: Legal Affairs 

  
 30 

 Unless an earlier date can be proven by competent evidence, the date of receipt of any notice
given under this Agreement, including, without limitation, any invoice provided by Manufacturer to Santarus, shall be deemed to be the date given if delivered personally or by facsimile transmission receipt verified, seven (7) days after the
date mailed, if mailed by registered or certified mail return receipt requested, postage prepaid, and two (2) days after the date sent if sent by express courier service. 

15.7 WAIVER. No failure of either Party to exercise and no delay in exercising any right, power or remedy in connection with this Agreement
(each a “RIGHT”) will operate as a waiver thereof, nor will any single or partial exercise of any Right preclude any other or further exercise of such Right or the exercise of any other Right. No waiver shall be effective unless made in
writing and signed by the waiving Party. 
 15.8 DISCLAIMER OF AGENCY. The relationship between Manufacturer and Santarus established by
this Agreement is that of independent contractors, and nothing contained in herein shall be construed to (i) give either Party the power to direct or control the day-to-day activities of the other, (ii) constitute the Parties as the legal
representative or agent of the other Party or as partners, joint venturers, co-owners or otherwise as participants in a joint or common undertaking, or (iii) allow either Party to create or assume any liability or obligation of any kind,
express or implied, against or in the name of or on behalf of the other Party for any purpose whatsoever, except as expressly set forth in this Agreement. 

15.9 SEVERABILITY. If any term, covenant or condition of this Agreement or the application thereof to any Party or circumstance shall, to any
extent, be held to be invalid or unenforceable by a court or administrative agency of competent jurisdiction, then the remainder of this Agreement, or the application of such term, covenant or condition to Parties or circumstances, other than those
as to which it is held invalid or unenforceable, shall not be affected thereby and each term, covenant or condition shall be valid and be enforced to the fullest extent permitted by law. 

15.10 ENTIRE AGREEMENT. This Agreement, including all schedules and exhibits attached hereto, and the Quality Agreement, which is hereby
incorporated herein by reference, set forth all covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto with respect to the manufacture and supply of commercial quantities of Finished
Product and supersedes and terminates all prior and contemporaneous agreements and understandings between the Parties with respect to such subject matter. 

15.11 MODIFICATION. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties hereto unless
reduced to writing and signed by the respective authorized officers of the Parties. In the event of a conflict between the terms of any Purchase Order, order acknowledgement, packaging slip or other documentation, and the terms of this Agreement,
the terms of this Agreement shall control, unless such documentation specifically states that it overrides conflicting terms of this Agreement and is signed by each of the Parties. 

  
 31 

 15.12 TRADEMARKS AND TRADE NAMES. The Parties hereby acknowledge that neither Party has, and
shall not acquire, any interest in any of the other Party’s trademarks or trade names appearing on the labels or packaging materials for the Finished Product unless otherwise expressly agreed in writing. 

15.13 CONSTRUCTION. This Agreement shall be deemed to have been drafted by all Parties and, in the event of a dispute, no Party hereto shall
be entitled to claim that any provision should be construed against any other Party by reason of the fact that it was drafted by one particular Party. The headings used in this Agreement are for convenience of reference only and are not a part of
the text hereof. 
 15.14 COUNTERPARTS. This Agreement may be executed in counterparts, by manual or facsimile signatures, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 In Witness Whereof, the Parties have
executed this Agreement in duplicate originals by their proper officers as of the Effective Date. 
  

									
	MANUFACTURER:	 		 	SANTARUS:
			
	OSG NORWICH PHARMACEUTICALS INC.	 		 	SANTARUS, INC.
					
	By: 	 	 /s/ Louis Ard
	 		 	 By: 
	 	 /s/ Gerald T. Proehl

	Name:	 	Louis Ard	 		 	 Name:
	 	 Gerald T. Proehl

	 Title: 
	 	 President
	 		 	 Title: 
	 	 President & CEO

  
 32 

 EXHIBIT A 

MINIMUM RUN QUANTITY 
 MINIMUM RUN QUANTITY 

[***] 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 33 

 EXHIBIT B 

PRICING INFORMATION 
 FINISHED PRODUCT: 

[***] 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 34 

 EXHIBIT C 

KEY PERFORMANCE INDICATORS 
 [***] 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 35

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]